SearchDictionaryMobileLogin

Gabriel N Hortobagyi Selected Research

Breast Neoplasms (Breast Cancer)

10/2008Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
09/2008Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
07/2008Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
06/2008Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
05/2008Use of intravenous bisphosphonates in older women with breast cancer.
04/2008Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
04/2008Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
03/2008Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
03/2008HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
01/2008Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
01/2008Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
01/2008Evaluation of biological pathways involved in chemotherapy response in breast cancer.
01/2008PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
10/2007Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
09/2007Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
08/2007Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
08/2007Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
07/2007Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
07/2007Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer.
07/2007Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
05/2007Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes.
05/2007Adjuvant biologic therapy for breast cancer.
04/2007Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
02/2007Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
01/2007Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
01/2007CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
12/2006DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.
12/2006Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma.
12/2006African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy.
10/2006Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
10/2006Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.
09/2006Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
09/2006Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
09/2006Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
09/2006A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
07/2006Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
06/2006Use and outcomes of adjuvant chemotherapy in older women with breast cancer.
02/2006Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.
12/2005Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
12/2005The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
12/2005Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.
11/2005Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
10/2005Cardiac morbidity of adjuvant radiotherapy for breast cancer.
10/2005Trastuzumab in the treatment of breast cancer.
10/2005Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
10/2005Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
09/2005Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
09/2005Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
08/2005CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
08/2005Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
06/2005Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
06/2005Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
06/2005Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
05/2005Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
03/2005Risk of cardiac death after adjuvant radiotherapy for breast cancer.
01/2005Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer.
01/2005Breast cancer biomarkers.
12/2004Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
11/2004Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
11/2004The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
06/2004The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
05/2004T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
03/2004Breast cancer biomarkers and molecular medicine: part II.
02/2004Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.
01/2004Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.
11/2003Nuclear factor-kappa B as a predictor of treatment response in breast cancer.
10/2003Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.
10/2003Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
10/2003Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
09/2003Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
09/2003Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
09/2003Breast cancer biomarkers and molecular medicine.
07/2003Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
07/2003A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
03/2003Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
03/2003Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
03/2003Estrogen receptors and distinct patterns of breast cancer relapse.
01/2003Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.
11/2002Cyclin E and survival in patients with breast cancer.
11/2002Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
11/2002Elevated luteinizing hormone in serum, breast cancer tissue, and normal breast tissue from breast cancer patients.
11/2002A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
10/2002Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience.
07/2002Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
07/2002Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
07/2002Adjuvant chemotherapy for breast cancer.
07/2002Neoadjuvant chemotherapy for operable breast cancer.
06/2002Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
06/2002Integration of docetaxel into adjuvant breast cancer treatment regimens.
05/2002Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer.
05/2002Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
04/2002Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
04/2002Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
02/2002Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
01/2002Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
01/2002Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.

Articles by Research Topic

Disease

96Breast Neoplasms (Breast Cancer)
10/2008 - 01/2002
22Carcinoma (Carcinomatosis)
06/2007 - 05/2002
16Neoplasms (Cancer)
06/2008 - 06/2002
6Neoplasm Metastasis (Metastasis)
01/2008 - 08/2005
2Residual Neoplasm
07/2007 - 10/2006
2Lobular Carcinoma
12/2006 - 01/2005
2Male Breast Neoplasms (Male Breast Cancer)
07/2006 - 06/2002
1Obesity
09/2008
1Pancreatic Neoplasms (Pancreatic Cancer)
09/2008
1Osteonecrosis (Kienbock's Disease)
06/2008
1Phyllodes Tumor (Cystosarcoma Phylloides)
11/2007
1Heart Failure
09/2007
1Inflammation
08/2007
1Noninfiltrating Intraductal Carcinoma (DCIS)
07/2007
1Ductal Carcinoma
12/2006
1Vasculitis (Vasculitides)
07/2006
1Death (Near-Death Experience)
03/2005
1Pneumonia (Pneumonitis)
11/2004
1Colitis
10/2004
1Neutropenia
01/2003
1Ovarian Neoplasms (Ovarian Cancer)
11/2002
1Pathologic Constriction (Stenosis)
06/2002

Drug/Important Bio-Agent (IBA)

13Paclitaxel (Taxol)FDA LinkGeneric
03/2008 - 05/2002
13Doxorubicin (Adriamycin)FDA LinkGeneric
11/2007 - 01/2002
9docetaxel (Taxotere)FDA Link
06/2008 - 01/2002
7trastuzumab (Herceptin)FDA Link
01/2007 - 04/2002
7Fluorouracil (Carac)FDA LinkGeneric
01/2007 - 01/2002
7Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2007 - 01/2002
6Biological Markers (Surrogate Marker)IBA
12/2006 - 06/2002
5Estrogens (Estrogen)FDA Link
10/2008 - 07/2003
4Epidermal Growth Factor Receptor (EGF Receptor)IBA
10/2007 - 06/2005
4taxaneIBA
08/2007 - 02/2002
3capecitabine (Xeloda)FDA Link
08/2007 - 09/2003
3Epirubicin (Ellence)FDA LinkGeneric
01/2007 - 06/2005
2DiphosphonatesIBA
06/2008 - 05/2008
2erlotinib (CP 358,774)FDA Link
08/2007 - 06/2007
2HormonesIBA
05/2007 - 03/2005
2tau Proteins (tau Protein)IBA
04/2007 - 06/2005
2TamoxifenFDA LinkGeneric
07/2006 - 01/2002
2gemcitabineFDA Link
09/2003 - 05/2002
2vinorelbine (Navelbine)FDA LinkGeneric
05/2002 - 01/2002
25-ethynyluracil (eniluracil)IBA
05/2002 - 02/2002
1Lysine (L-Lysine)FDA Link
09/2008
1Histones (Histone)IBA
09/2008
1lapatinib (GW572016)FDA Link
07/2008
1Cisplatin (Platino)FDA LinkGeneric
05/2008
1Dacarbazine (DIC)FDA LinkGeneric
11/2007
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
10/2007
1ixabepilone (BMS 247550)FDA Link
08/2007
1I-kappa B KinaseIBA
08/2007
1Cyclin-Dependent Kinase 2IBA
08/2007
1DNA (Deoxyribonucleic Acid)IBA
12/2006
1CyclinsIBA
10/2006
1Phosphotransferases (Kinase)IBA
10/2006
1temozolomide (Temodar)FDA Link
09/2006
1Aromatase (CYP19)IBA
07/2006
1Leuprolide (Lupron)FDA LinkGeneric
07/2006
1Cytosine DeaminaseIBA
01/2006
1EndostatinsIBA
01/2006
1Transcription Factors (Transcription Factor)IBA
12/2005
1ParaffinIBA
10/2005
1albumin-bound paclitaxelFDA Link
09/2005
1tariquidar (XR9576)IBA
08/2005
1P-GlycoproteinIBA
08/2005
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
05/2005
1Carmustine (FIVB)FDA Link
11/2004
1Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric
11/2004
1TaxoidsIBA
07/2004
1Protein Kinases (Protein Kinase)IBA
02/2004
1Proteins (Proteins, Gene)IBA
01/2004
1fludarabineIBA
11/2003
1Melphalan (Alkeran)FDA Link
11/2003
1NF-kappa B (NF-kB)IBA
11/2003
1sulindac sulfone (exisulind)IBA
09/2003
1pegylated liposomal doxorubicinIBA
09/2003
1DX 8951 (DX 8951f)IBA
09/2003
1Filgrastim (Neupogen)FDA Link
07/2003
1RNA (Ribonucleic Acid)IBA
06/2003
1bexarotene (LGD1069)FDA Link
03/2003
1Estrogen ReceptorsIBA
03/2003
1Cyclin EIBA
11/2002
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
11/2002
1Luteinizing Hormone (Lutropin)FDA LinkGeneric
11/2002
1annamycinIBA
07/2002
1anastrozole (Arimidex)FDA Link
06/2002
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2002

Therapy/Procedure

55Drug Therapy (Chemotherapy)
09/2008 - 06/2002
9Adjuvant Chemotherapy
10/2008 - 05/2002
6Mastectomy (Mammectomy)
12/2006 - 07/2002
5Neoadjuvant Therapy
03/2008 - 06/2005
2Adjuvant Radiotherapy
10/2005 - 03/2005
1Biological Therapy
05/2007
1Hematopoietic Stem Cell Transplantation
11/2004
1Aftercare (After-Treatment)
02/2004
1Stem Cell Transplantation
11/2003
1Estrogen Replacement Therapy
11/2002